Stock FPH FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Fisher & Paykel Healthcare Corporation Limited Australian S.E.

Equities

FPH

NZFAPE0001S2

Market Closed - Australian S.E.
Other stock markets
 07:10:46 30/04/2024 BST 		5-day change 1st Jan Change
25.82 AUD +1.69% Intraday chart for Fisher & Paykel Healthcare Corporation Limited +5.99% +18.28%
04-09 New Zealand Shares Fall for Second Day; Fisher & Paykel Healthcare Launches Apnea Mask MT
04-09 Fisher & Paykel Begins Selling Lightest Mask for Sleep Apnea MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's high margin levels account for strong profits.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • The opinion of analysts covering the stock has improved over the past four months.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

Weaknesses

  • With an expected P/E ratio at 63.47 and 48.8 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is highly valued given the cash flows generated by its activity.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED Stock Fisher & Paykel Healthcare Corporation Limited
+18.28% 9.76B -
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.54% 186B
C+
MEDTRONIC PLC Stock Medtronic plc
-1.85% 107B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-4.26% 67.44B
A
DEXCOM, INC. Stock DexCom, Inc.
+1.39% 50.03B
B-
CENCORA, INC. Stock Cencora, Inc.
+16.82% 47.81B
B-
HOYA CORPORATION Stock Hoya Corporation
+4.79% 41.03B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+3.49% 26.85B
B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+0.65% 25.82B
A-
TERUMO CORPORATION Stock Terumo Corporation
+16.55% 24.74B
A-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. FPH Stock
  4. FPH Stock
  5. Ratings Fisher & Paykel Healthcare Corporation Limited